RESUMO
Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53-year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma.
Assuntos
Anti-Inflamatórios/efeitos adversos , Anticorpos Monoclonais/efeitos adversos , Hipergamaglobulinemia/complicações , Imunoglobulina A , Mieloma Múltiplo/induzido quimicamente , Pioderma Gangrenoso/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Progressão da Doença , Humanos , Infliximab , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/patologia , Lesões Pré-Cancerosas/patologiaRESUMO
Genetic factors are known to be important in the development of Hodgkin lymphoma (HL). Interleukin-10 (IL-10) secretion by both malignant and reactive cells is thought to be important in the pathogenesis of HL especially Epstein-Barr virus (EBV) positive cases. Polymorphisms of the IL-10 gene have been reported to be associated with susceptibility to EBV infection. The cytotoxic response to EBV is determined by a Th1 biased immune response which is characterised by interferon gamma (IFNgamma) secretion. We therefore investigated polymorphisms in the IL-10 (-1082 G/A and -592 C/A) and IFNgamma (intron 1 CA repeat) genes as predisposing factors in the development 147 cases of HL. A difference of borderline statistical significance was demonstrated for the IFNgamma gene polymorphism but significance was lost when analysis was restricted to the common genotypes. No significant differences in the distributions of genotypes were found for the IL-10 gene polymorphisms. IL-10 and IFNgamma levels were also measured on 26 patients with HL. No statistically significant differences were detected when the results were analysed by genotype. We found little evidence IL-10 and IFNgamma genotypes predispose to the development of HL or influence the inflammatory host response.
Assuntos
Doença de Hodgkin/genética , Interferon gama/genética , Interleucina-10/genética , Polimorfismo Genético , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Concanavalina A/metabolismo , Feminino , Genótipo , Haplótipos , Herpesvirus Humano 4/metabolismo , Humanos , Inflamação , Interferon gama/metabolismo , Interleucina-10/metabolismo , Íntrons , Masculino , Pessoa de Meia-IdadeRESUMO
BACKGROUND AND OBJECTIVES: Routine irradiation of cellular blood products is not presently recommended for patients with non-Hodgkin's lymphoma (NHL). MATERIALS AND METHODS: We report the case of a 72-year-old-man with Waldenstrom's macroglobulinaemia who developed transfusion-associated graft-versus-host disease (TA-GvHD) 13 days following a non-irradiated red cell transfusion. RESULTS: The patient had not previously received purine analogues and none of the donors was homozygous for a human leucocyte antigen (HLA) haplotype that was shared by the recipient. Therefore, his only apparent risk factor was lymphoplasmacytoid NHL. CONCLUSIONS: This case further strengthens the argument that NHL per se is a risk factor for TA-GvHD and supports the proposal that the guidelines for prophylactic irradiation of cellular blood products be extended to include all cases of NHL.
Assuntos
Transfusão de Eritrócitos/efeitos adversos , Doença Enxerto-Hospedeiro/etiologia , Macroglobulinemia de Waldenstrom/complicações , Idoso , Incompatibilidade de Grupos Sanguíneos , Tipagem e Reações Cruzadas Sanguíneas , Doença Enxerto-Hospedeiro/diagnóstico , Humanos , Leucemia Linfocítica Crônica de Células B , Masculino , Esterilização , Macroglobulinemia de Waldenstrom/terapiaAssuntos
Linfoma de Célula do Manto/complicações , Linfoma de Célula do Manto/microbiologia , Adulto , Antígenos CD/metabolismo , Feminino , Humanos , Hospedeiro Imunocomprometido , Linfoma de Célula do Manto/classificação , Linfoma de Célula do Manto/terapia , Pessoa de Meia-Idade , Proteínas de Neoplasias/metabolismoRESUMO
We report a novel chromosomal translocation (X;5)(q13;q33) in a woman with no history of prior chemotherapy or radiotherapy, found to have essential thrombocythemia. Aberrations in chromosome 5, mostly deletions of 5q, have been described in essential thrombocythemia; however, a t(X;5) translocation has not been reported.
